Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Ashford Capital Management Inc.

Ashford Capital Management Inc. lifted its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 0.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 545,775 shares of the specialty pharmaceutical company’s stock after buying an additional 1,740 shares during the period. Supernus Pharmaceuticals makes up approximately 2.3% of Ashford Capital Management Inc.’s investment portfolio, making the stock its 18th biggest holding. Ashford Capital Management Inc. owned 0.99% of Supernus Pharmaceuticals worth $19,735,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in SUPN. Barclays PLC raised its stake in Supernus Pharmaceuticals by 88.3% in the 3rd quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock worth $3,393,000 after acquiring an additional 51,005 shares during the last quarter. Franklin Resources Inc. increased its holdings in shares of Supernus Pharmaceuticals by 7.6% in the third quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company’s stock valued at $987,000 after purchasing an additional 2,121 shares during the period. Principal Financial Group Inc. raised its stake in shares of Supernus Pharmaceuticals by 5.4% in the third quarter. Principal Financial Group Inc. now owns 285,411 shares of the specialty pharmaceutical company’s stock worth $8,899,000 after purchasing an additional 14,566 shares during the last quarter. Wedge Capital Management L L P NC acquired a new stake in shares of Supernus Pharmaceuticals during the fourth quarter worth about $1,928,000. Finally, Mitsubishi UFJ Asset Management UK Ltd. boosted its position in Supernus Pharmaceuticals by 12.5% in the fourth quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 27,000 shares of the specialty pharmaceutical company’s stock valued at $976,000 after buying an additional 3,000 shares during the last quarter.

Supernus Pharmaceuticals Stock Performance

NASDAQ SUPN opened at $33.05 on Tuesday. The firm has a market capitalization of $1.85 billion, a P/E ratio of 30.89 and a beta of 0.74. The stock has a 50-day simple moving average of $31.92 and a two-hundred day simple moving average of $34.83. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $40.28.

Insider Buying and Selling

In related news, SVP Jonathan Rubin sold 927 shares of the stock in a transaction on Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the sale, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at approximately $307,444.95. This represents a 10.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 8.80% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

SUPN has been the topic of several research reports. StockNews.com upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.